Arkolith/Insider Trading/BCAX/Form 4

Mazumdar Claire

Chief Executive Officer, DirectorBicara Therapeutics Inc. (BCAX) · full profile →Form 4 · filed Mar 20, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$282K
Net Open-Market Flow
-$282K
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 20, 2026Sell(S)2K$18.95$30K339K
Mar 20, 2026Option exercise(M)2K$3.79$6K341K
Mar 19, 2026Sell(S)7K$18.78$130K339K
Mar 19, 2026Option exercise(M)7K$3.79$26K346K
Mar 18, 2026Sell(S)6K$18.84$122K339K
Mar 18, 2026Option exercise(M)6K$3.79$25K346K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 20, 2026Option exercise(M)2K—$0176K
Mar 19, 2026Option exercise(M)7K—$0178K
Mar 18, 2026Option exercise(M)6K—$0185K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-020236) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML